Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia

References

• Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood82(1), 1–14 (1993).
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP Jr. Clinical features of large granular lymphocyte leukemia. Semin. Hematol.40(3), 185–195 (2003).
   PubMed Web of Science ®Google Scholar
• Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol.20, 323–370 (2002).
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist11(3), 263–273 (2006).
   PubMed Web of Science ®Google Scholar
• Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica94(10), 1341–1345 (2009).
   PubMed Web of Science ®Google Scholar
• Chan WC, Foucar KM, Morice WG, Catovsky D. T-cell large granular lymphocyte leukaemia. In: WHO Classification of Tumours of the Hematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). IARC Press, Lyon, France, 272–273 (2008).
   Google Scholar
• Villamor N, Morice WG, Chan WC, Foucar K. Chronic lyphoproliferative disorders of NK cells. In: WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). IARC Press, Lyon, France, 274–275 (2008).
   Google Scholar
• Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to ‘benign monoclonal gammapathy’. J. Exp. Med.179(2), 609–618 (1994).
   PubMed Web of Science ®Google Scholar
• Ricalton NS, Roberton C, Norris JM, Rewers M, Hamman RF, Kotzin BL. Prevalence of CD8+ T-cell expansions in relation to age in healthy individuals. J. Gerontol. A Biol. Sci. Med. Sci.53(3), B196–B203 (1998).
   Google Scholar
• Bigouret V, Hoffmann T, Arlettaz L et al. Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors. Blood101(8), 3198–3204 (2003).
   PubMed Web of Science ®Google Scholar
• Clambey ET, van Dyk LF, Kappler JW, Marrack P. Non-malignant clonal expansions of CD8+ memory T cells in aged individuals. Immunol. Rev.205, 170–189 (2005).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood84(5), 1620–1627 (1994).
   PubMed Web of Science ®Google Scholar
• Sabnani I, Tsang P. Are clonal T-cell large granular lymphocytes to blame for unexplained haematological abnormalities? Br. J. Haematol.136(1), 30–37 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang R, Shah MV, Loughran TP Jr. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol. Oncol.28(3), 105–117 (2010).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood84(8), 2721–2725 (1994).
   PubMed Web of Science ®Google Scholar
• Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br. J. Haematol.139(4), 532–544 (2007).
   PubMed Web of Science ®Google Scholar
• Zambello R, Trentin L, Facco M et al. Analysis of the T cell receptor in the lymphoproliferative disease of granular lymphocytes: superantigen activation of clonal CD3+ granular lymphocytes. Cancer Res.55(24), 6140–6145 (1995).
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Loughran TP Jr. Survival signals in leukemic large granular lymphocytes. Semin. Hematol.40(3), 213–220 (2003).
   PubMed Web of Science ®Google Scholar
• Yang J, Epling-Burnette PK, Painter JS et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood111(3), 1610–1616 (2008).
   PubMed Web of Science ®Google Scholar
• Zambello R, Berno T, Cannas G et al. Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood106(12), 3926–3931 (2005).
   PubMed Web of Science ®Google Scholar
• Wlodarski MW, O’Keefe C, Howe EC et al. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood106(8), 2769–2780 (2005).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr. Chronic T-cell leukemia/lymphoma. Cancer Control5(1), 8–9 (1998).
   PubMedGoogle Scholar
• Sokol L, Agrawal D, Loughran TP Jr. Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk. Res.29(4), 381–387 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Caballero A, Garcia-Montero AC, Barcena P et al. Expanded cells in monoclonal TCR-αβ+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood112(12), 4609–4616 (2008).
   PubMed Web of Science ®Google Scholar
• Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br. J. Haematol.152(3), 273–283 (2011).
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP Jr. Current concepts: large granular lymphocyte leukemia. Blood Rev.13(4), 230–240 (1999).
   PubMed Web of Science ®Google Scholar
• Burks EJ, Starkebaum G, Loughran TP Jr. Section III. Large granular lyphocyte leukemia and neutropenia. In: Congenital and Acquired Neutropenia. Berliner N, Horwitz M, Loughran TP Jr (Eds). Hematology: American Society of Hematology Education Program Book, 63–79 (2004).
   Google Scholar
• Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev.20(5), 245–266 (2006).
   PubMed Web of Science ®Google Scholar
• Shah MV, Zhang R, Loughran TP Jr. Never say die: survival signaling in large granular lymphocyte leukemia. Clin. Lymphoma Myeloma.9(Suppl. 3), S244–S253 (2009).
   PubMedGoogle Scholar
• Krammer PH. CD95’s deadly mission in the immune system. Nature407(6805), 789–795 (2000).
   PubMed Web of Science ®Google Scholar
• Lamy T, Liu JH, Landowski TH, Dalton WS, Loughran TP Jr. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3+ large granular lymphocyte leukemia. Blood92(12), 4771–4777 (1998).
   PubMed Web of Science ®Google Scholar
• Liu JH, Wei S, Lamy T et al. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood100(4), 1449–1453 (2002).
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Liu JH, Catlett-Falcone R et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest107(3), 351–362 (2001).
   PubMed Web of Science ®Google Scholar
• Schade AE, Wlodarski MW, Maciejewski JP. Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. Cell Cycle5(22), 2571–2574 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang R, Shah MV, Yang J et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc. Natl Acad. Sci. USA105(42), 16308–16313 (2008).
   PubMed Web of Science ®Google Scholar
• Shah MV, Zhang R, Irby R et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood112(3), 770–781 (2008).
   PubMed Web of Science ®Google Scholar
• Zambello R, Falco M, Della CM et al. Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood102(5), 1797–1805 (2003).
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Painter JS, Chaurasia P et al. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood103(9), 3431–3439 (2004).
   PubMed Web of Science ®Google Scholar
• Zambello R, Loughran TP Jr, Trentin L et al. Serologic and molecular evidence for a possible pathogenetic role of viral infection in CD3-negative natural killer-type lymphoproliferative disease of granular lymphocytes. Leukemia9(7), 1207–1211 (1995).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Hadlock KG, Yang Q et al. Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Blood90(5), 1977–1981 (1997).
   PubMed Web of Science ®Google Scholar
• Scquizzato E, Teramo A, Miorin M et al. Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia21(5), 1060–1069 (2007).
   PubMed Web of Science ®Google Scholar
• Gattazzo C, Teramo A, Miorin M et al. Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. Haematologica95(10), 1722–1729 (2010).
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Bai F, Wei S et al. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene23(57), 9220–9229 (2004).
   PubMed Web of Science ®Google Scholar
• Hodge DL, Yang J, Buschman MD et al. Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res.69(9), 3986–3994 (2009).
   PubMed Web of Science ®Google Scholar
• Yang J, Liu X, Nyland SB et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood115(1), 51–60 (2010).
   PubMed Web of Science ®Google Scholar
• Yu J, Ershler M, Yu L et al. TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. Blood113(22), 5558–5567 (2009).
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Pontikoglou C. Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia. Expert. Rev. Hematol.1(2), 217–229 (2008).
   PubMed Web of Science ®Google Scholar
• Prochorec-Sobieszek M. Advances in diagnosis and treatment of large granular lymphocyte syndrome. Curr. Opin. Hematol.18(1), 55–62 (2011).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Starkebaum G. Large granular lymphocyte leukemia. Report of 38 cases and review of the literature. Medicine66(5), 397–405 (1987).
   PubMed Web of Science ®Google Scholar
• Evans HL, Burks E, Viswanatha D, Larson RS. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia. Hum. Pathol.31(10), 1266–1273 (2000).
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood99(1), 268–274 (2002).
   PubMed Web of Science ®Google Scholar
• Sood R, Stewart CC, Aplan PD et al. Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood91(9), 3372–3378 (1998).
   PubMed Web of Science ®Google Scholar
• Hansson M, Beran M, Andersson B, Kiessling R. Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J. Immunol.129(1), 126–132 (1982).
   PubMed Web of Science ®Google Scholar
• Matera L, Santoli D, Garbarino G, Pegoraro L, Bellone G, Pagliardi G. Modulation of in vitro myelopoiesis by LGL: different effects on early and late progenitor cells. J. Immunol.136(4), 1260–1265 (1986).
   PubMed Web of Science ®Google Scholar
• Coakley G, Iqbal M, Brooks D, Panayi GS, Lanchbury JS. CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty’s and large granular lymphocyte syndromes. Arthritis Rheum.43(4), 834–843 (2000).
   PubMed Web of Science ®Google Scholar
• Reynolds CW, Foon KA. T gamma-lymphoproliferative disease and related disorders in humans and experimental animals: a review of the clinical, cellular, and functional characteristics. Blood64(6), 1146–1158 (1984).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Kadin ME, Starkebaum G et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann. Intern. Med.102(2), 169–175 (1985).
   PubMed Web of Science ®Google Scholar
• Grillot-Courvalin C, Vinci G, Tsapis A, Dokhelar MC, Vainchenker W, Brouet JC. The syndrome of T8 hyperlymphocytosis: variation in phenotype and cytotoxic activities of granular cells and evaluation of their role in associated neutropenia. Blood69(4), 1204–1210 (1987).
   PubMed Web of Science ®Google Scholar
• Platanias L, Raefsky E, Young N. Neutropenia associated with large granular lymphocytes responsive to corticosteroids in vitro and in vivo. Eur. J. Haematol.38(1), 89–94 (1987).
   PubMed Web of Science ®Google Scholar
• Starkebaum G, Martin PJ, Singer JW et al. Chronic lymphocytosis with neutropenia: evidence for a novel, abnormal T-cell population associated with antibody-mediated neutrophil destruction. Clin. Immunol. Immunopathol.27(1), 110–123 (1983).
   PubMedGoogle Scholar
• van der Veen JP, Goldschmeding R, Miedema F, Smit JW, Melief CJ, von dem Borne AE. K-cell lymphocytosis/neutropenia syndrome: the neutropenia is not caused by autoimmunity. Br. J. Haematol.64(4), 777–787 (1986).
   PubMed Web of Science ®Google Scholar
• Rustagi PK, Han T, Ziolkowski L, Farolino DL, Currie MS, Logue GL. Granulocyte antibodies in leukaemic chronic lymphoproliferative disorders. Br. J. Haematol.66(4), 461–465 (1987).
   PubMed Web of Science ®Google Scholar
• Liu JH, Wei S, Lamy T et al. Chronic neutropenia mediated by Fas ligand. Blood95(10), 3219–3222 (2000).
   PubMed Web of Science ®Google Scholar
• Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med.184(2), 429–440 (1996).
   PubMed Web of Science ®Google Scholar
• Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J.14(6), 1129–1135 (1995).
   PubMed Web of Science ®Google Scholar
• Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nat. Med.2(3), 317–322 (1996).
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin. Hematol.40(3), 221–232 (2003).
   PubMed Web of Science ®Google Scholar
• Reichard KK, Burks EJ, Foucar MK et al. CD4+ CD56+ lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am. J. Surg. Pathol.29(10), 1274–1283 (2005).
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Shibuya T, Harada M et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood86(3), 883–889 (1995).
   PubMed Web of Science ®Google Scholar
• Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood85(11), 3183–3190 (1995).
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br. J. Haematol.91(1), 245–252 (1995).
   PubMed Web of Science ®Google Scholar
• Bank I, Cohen L, Kneller A, De Rosbo NK, Book M, Ben-Nun A. Aberrant T-cell receptor signalling of interferon-γ- and tumour necrosis factor-α-producing cytotoxic CD8+ Vδ1/Vβ16 T cells in a patient with chronic neutropenia. Scand. J. Immunol.58(1), 89–98 (2003).
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Chatzivassili A, Stefanaki K, Koumaki V, Kanavaros P, Eliopoulos GD. Morphologically defined myeloid cell compartments, lymphocyte subpopulations, and histological findings of bone marrow in patients with nonimmune chronic idiopathic neutropenia of adults. Ann. Hematol.79(10), 563–570 (2000).
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Eliopoulos AG, Kosteas T et al. Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells. Blood101(7), 2591–2600 (2003).
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Stamatopoulos K, Damianaki A et al. Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia. Br. J. Haematol.128(6), 863–876 (2005).
   PubMed Web of Science ®Google Scholar
• Spanoudakis M, Koutala H, Ximeri M, Pyrovolaki K, Stamatopoulos K, Papadaki HA. T-cell receptor Vβ repertoire analysis in patients with chronic idiopathic neutropenia demonstrates the presence of aberrant T-cell expansions. Clin. Immunol.137(3), 384–395 (2010).
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Tsagournisakis M, Mastorodemos V et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant.36(12), 1053–1063 (2005).
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Papadaki T, Pontikoglou C et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia22(7), 1446–1449 (2008).
   PubMed Web of Science ®Google Scholar
• Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine89(5), 308–318 (2010).
   PubMed Web of Science ®Google Scholar
• Viny AD, Clemente MJ, Jasek M et al. MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia. Haematologica95(10), 1713–1721 (2010).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Hammond WP. Adult-onset cyclic neutropenia is a benign neoplasm associated with clonal proliferation of large granular lymphocytes. J. Exp. Med.164(6), 2089–2094 (1986).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Clark EA, Price TH, Hammond WP. Adult-onset cyclic neutropenia is associated with increased large granular lymphocytes. Blood68(5), 1082–1087 (1986).
   PubMed Web of Science ®Google Scholar
• Dale DC, Hammond WP. Cyclic neutropenia: a clinical review. Blood Rev.2(3), 178–185 (1988).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Starkebaum G, Aprile JA. Rearrangement and expression of T-cell receptor genes in large granular lymphocyte leukemia. Blood71(3), 822–824 (1988).
   PubMed Web of Science ®Google Scholar
• Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology Am. Soc. Hematol. Educ. Program259–281 (2001).
   PubMedGoogle Scholar
• Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist9(3), 247–258 (2004).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood84(7), 2164–2170 (1994).
   PubMed Web of Science ®Google Scholar
• Hamidou MA, Sadr FB, Lamy T, Raffi F, Grolleau JY, Barrier JH. Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. Am. J. Med.108(9), 730–732 (2000).
   PubMed Web of Science ®Google Scholar
• Osuji N, Matutes E, Tjonnfjord G et al. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer107(3), 570–578 (2006).
   PubMed Web of Science ®Google Scholar
• Bareau B, Rey J, Hamidou M et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica95(9), 1534–1541 (2010).
   PubMed Web of Science ®Google Scholar
• Pastor E, Sayas MJ. Severe neutropenia associated with large granular lymphocyte lymphocytosis: successful control with cyclosporin A. Blut59(6), 501–502 (1989).
   PubMedGoogle Scholar
• Gabor EP, Mishalani S, Lee S. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood87(3), 1199–1200 (1996).
   PubMed Web of Science ®Google Scholar
• Brinkman K, van Dongen JJ, van Lom K, Groeneveld K, Misere JF, van der Heul C. Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vβ antibodies. Leukemia12(2), 150–154 (1998).
   PubMed Web of Science ®Google Scholar
• Battiwalla M, Melenhorst J, Saunthararajah Y et al. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br. J. Haematol.123(3), 449–453 (2003).
   PubMed Web of Science ®Google Scholar
• Aribi A, Huh Y, Keating M et al. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk. Res.31(7), 939–945 (2007).
   PubMed Web of Science ®Google Scholar
• Thomssen C, Nissen C, Gratwohl A, Tichelli A, Stern A. Agranulocytosis associated with T-gamma-lymphocytosis: no improvement of peripheral blood granulocyte count with human-recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). Br. J. Haematol.71(1), 157–158 (1989).
   PubMed Web of Science ®Google Scholar
• Mulder AB, de Wolf JT, Smit JW, van Oostveen JW, Vellenga E. Correction of neutropenia by GM-CSF in patients with a large granular lymphocyte proliferation. Ann. Hematol.65(2), 91–95 (1992).
   PubMed Web of Science ®Google Scholar
• Cooper DL, Henderson-Bakas M, Berliner N. Lymphoproliferative disorder of granular lymphocytes associated with severe neutropenia. Response to granulocyte colony-stimulating factor. Cancer72(5), 1607–1611 (1993).
   PubMed Web of Science ®Google Scholar
• Vickers M, Stross P, Millard P, Barton C. Response of T-β CD8+ lymphocytosis-associated neutropenia to G-CSF. Br. J. Haematol.87(2), 431–433 (1994).
   PubMed Web of Science ®Google Scholar
• Lamy T, LePrise PY, Amiot L et al. Response to granulocyte-macrophage colony-stimulating factor (GM-CSF) but not to G-CSF in a case of agranulocytosis associated with large granular lymphocyte (LGL) leukemia. Blood85(11), 3352–3353 (1995).
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Starkebaum G, Clark E, Wallace P, Kadin ME. Evaluation of splenectomy in large granular lymphocyte leukaemia. Br. J. Haematol.67(2), 135–140 (1987).
   PubMed Web of Science ®Google Scholar
• Subbiah V, Viny AD, Rosenblatt S, Pohlman B, Lichtin A, Maciejewski JP. Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Exp. Hematol.36(9), 1078–1083 (2008).
   PubMed Web of Science ®Google Scholar
• Imamura N, Kuramoto A. Effect of splenectomy in aggressive large granular lymphocyte leukaemia. Br. J. Haematol.69(4), 577–578 (1988).
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood87(7), 3000–3006 (1996).
   PubMed Web of Science ®Google Scholar
• Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood98(2), 483–485 (2001).
   PubMed Web of Science ®Google Scholar
• Osuji N, Del Giudice I, Matutes E et al. CD52 expression in T-cell large granular lymphocyte leukemia – implications for treatment with alemtuzumab. Leuk. Lymphoma46(5), 723–727 (2005).
   PubMed Web of Science ®Google Scholar
• Mohan SR, Clemente MJ, Afable M et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica94(10), 1407–1414 (2009).
   PubMed Web of Science ®Google Scholar
• Sternberg A, Eagleton H, Pillai N et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. Br. J. Haematol.120(4), 699–701 (2003).
   PubMed Web of Science ®Google Scholar
• Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol.12(12), 2588–2593 (1994).
   PubMed Web of Science ®Google Scholar
• Granjo E, Lima M, Correia T et al. CD8+/V β 5. 1+ large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin. Hematol. Oncol.20(2), 87–93 (2002).
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood7(10), 2764–2774 (2011).
   Google Scholar
• Wymann MP, Schneiter R. Lipid signalling in disease. Nat. Rev. Mol. Cell Biol.9(2), 162–176 (2008).
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood100(2), 474–482 (2002).
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Kritikos HD, Gemetzi C et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor α-mediated effect. Blood99(5), 1610–1619 (2002).
   PubMed Web of Science ®Google Scholar